Beta Bionics, Inc. Q3 2026 Earnings Conference Call & Webcast - BETA BIONICS INC

Financial Performance:

• Q3 2026 net sales reached a record $35.5 million, representing approximately 30% year-over-year growth.
• Gross margin stood at 57.3% for the quarter, expanding 179 basis points year-over-year but declining 178 basis points sequentially due to unfavorable mix from DME distributor stocking of lower-margin supplies.
• Total operating expenses increased 46% year-over-year to $46.9 million, driven by expansion of the sales force, marketing investments, and R&D costs for Mint and bi-hormonal projects.
• The company raised approximately $161 million in net proceeds from a public offering completed in September, bringing total cash, equivalents, and investments to $374 million as of September 30, 2026.
• High-margin recurring revenue from the pharmacy channel remains a key driver, with pharmacy new patient starts in the high 30s percent of total new starts.

Guidance and Future Outlook:

• Updated full-year 2026 revenue guidance raised to $124 million–$126 million, reflecting a fourth-quarter revenue contribution of $29 million–$31 million.
• Full-year gross margin guidance reiterated at 58.5%–59.5%, with expectations that Q3 mix unfavorable dynamics will normalize in Q4.
• Pharmacy reimbursement channel is expected to account for 37%–39% of new patient starts for the full year.
• Mint is projected to launch commercially in the U.S. in Q1 2027 with an expected ramp of at least 1.5 million units for the year.
• Management expects to exceed current patch pump incumbent gross margins within three years post-Mint launch due to favorable cost design of durable vs. disposable components.
• Pharmacy coverage for Mint is projected at ~40% of U.S. lives at launch, growing to ~50% by year-end 2027.

Business Segments and Product Lines:

• Mint Patch Pump: Received FDA clearance in September; designed as the smallest automated insulin delivery (AID) patch in the U.S., featuring a non-rechargeable design, integration with leading CGMs, and control via iOS/Android. User feedback indicates insertion is perceived as less painful than competitive patch pumps.
• 3D Intelligence Algorithm: A new generation algorithm offering three options to tailor insulin delivery; 510(k) submission withdrawn to resubmit with additional simulator validation data, with a revised submission expected mid-Q4 2026.
• Islet: Continued strong performance with new patient starts growing mid-single-digit sequentially; Type 2 patients now represent >30% of new starts (off-label), with a real-world pivotal trial fully enrolled to seek Type 2 indication.
• Innovation Pipeline: Initiation of a pivotal trial for a "fully closed-loop" algorithm (removing meal announcements) in both Type 1 and Type 2 diabetes expected in coming weeks; bi-hormonal system drug reformulation complete with Phase IIA trials underway.
• Integrations: Launching Islet integration with Dexcom Libre (Sensonic's Eversense 365) in Q4 2026; Mint integration to follow.

Market and Competitive Landscape:

• Mint is positioned as a transformative, fully adaptive, and most advanced AID patch pump, competing directly with existing tubeless options.
• Management anticipates Mint will expand the overall market and capture share, noting that ~90% of surveyed current Islet users would switch to Mint if out-of-pocket costs were equal.
• The company leverages existing PBMS relationships and the "patch pump" reimbursement classification (Medicare Part D) to streamline market access for Mint compared to tubed pump processes.
• Competitors are launching other patch pumps, but Beta Bionics emphasizes Mint's unique features: smallest form factor, no recharging, and superior algorithm adaptability.

Risks and Challenges:

• Regulatory Delays: The 3D Intelligence algorithm submission was delayed, requiring resubmission and potentially pushing clearance to 2027, though Q4 2026 clearance remains a possibility.
• Supply Chain and Capacity: Initial Mint production starts near zero with a single manufacturing line; capacity will expand by adding shifts and replicating lines throughout 2027 to meet the 1.5 million unit target.
• Revenue Deferral: Anticipated revenue deferral from prospective users waiting for Mint was revised down to $8.5 million (from a prior estimate of $10 million), reflecting lower than expected patient awareness of the new product.
• Manufacturing Costs: Mint is expected to be dilutive to gross margins in 2027, though management projects long-term accretion due to cost-effective design of the disposable component.
• Awareness Gap: Lower-than-expected patient awareness of Mint compared to Islet led to conservative revenue guidance, requiring significant sales force efforts to inform healthcare providers.

Management Commentary and Tone:

• Tone was confident and enthusiastic, with the CEO labeling Mint clearance as the company's "largest milestone to date" and calling it a "game changer."
• Management expressed strong conviction in the product's design, citing a fast three-year timeline from concept to clearance.
• CFO Stephen Fiverr and CEO Sean Saint demonstrated discipline in capital allocation, emphasizing the need to scale operations while maintaining a path to positive free cash flow.
• Management acknowledged the 3D Intelligence regulatory setback as procedural (simulator validation time) rather than a flaw in the algorithm itself.

Analyst Questions and Answers:

• Simulator Validation: Management clarified the 3D Intelligence withdrawal was due to the FDA requesting additional validation of the simulation methodology (trust in the simulator's output), not concerns with the algorithm's performance or patient outcomes.
• Mint Ramp and Capacity: Clarified that commercial shipments begin in Q1 2027; initial capacity is constrained, prioritizing new users, with ramp modeled as linear through the year.
• Type 2 Indication: Real-world trial enrollment is complete; approval and launch for Type 2 diabetes are expected mid-2027, utilizing the current Islet algorithm mode as a baseline.
• Fully Closed-Loop: Management defended the "forced fully closed-loop" approach (no meal announcements) as safer for the broader population (including primary care settings) and effective at reducing hypoglycemia risks compared to standard care.
• Market Access: Confirmed Mint's classification as a patch pump simplifies reimbursement; existing pharmacy contracts will aid in achieving ~40-50% coverage quickly.
• Churn and Retention: Reported strong retention with Type 2 retention slightly exceeding Type 1 retention, indicating no negative market impacts from competitor earnings releases.

Other Key Points:

• Capital Expenditures: Expected to spend in the low-to-mid single-digit millions in Q4 2026, with significant CapEx in 2027 focused on expanding Mint manufacturing lines.
• Sales Force Strategy: Expanded the field sales organization significantly ahead of the Mint launch to ensure rapid education of healthcare providers.
• Bi-hormonal System: Back on track with reformulation complete; further updates to be provided as Phase IIA trials progress.
• Executive Note: The CEO personally wore the Mint device during the call to validate the user experience.